Other
Payments To Acquire Restricted Investments
Year-over-year, this metric declined by 91.6%, from $48.83M to $4.10M. Over 3 years (FY 2021 to FY 2025), Payments To Acquire Restricted Investments shows an upward trend with a 12.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase represents a tie-up of capital in restricted assets, potentially reducing immediate liquidity.
Detailed definition
Cash outflows dedicated to acquiring restricted investments or assets that are not readily available for general corpora...
Peer comparison
Specific to companies with complex regulatory or contractual collateral requirements.
Metric ID:
other_payments_to_acquire_restricted_investmentsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $165.00K | $15.33M | $16.00M | $9.40M | $23.33M | $49.23M | $9.25M | $0.00 | $0.00 | $39.98M | $17.90M | $19.20M | $0.00 | $48.83M | $9.25M | $1.70M | $0.00 | $4.10M |
| QoQ Change | — | >999% | +4.4% | -41.3% | +148.1% | +111.0% | -81.2% | -100.0% | — | — | -55.2% | +7.3% | -100.0% | — | -81.1% | -81.6% | -100.0% | — |
| YoY Change | — | — | — | — | >999% | +423.7% | -60.3% | — | — | -18.8% | +93.5% | — | — | +22.1% | -48.3% | -91.1% | — | -91.6% |
Range$0.00 – $49.23M
CAGR+113.0%
Avg YoY Growth>999%
Median YoY Growth-18.8%
Current Streak4 quarters decline
Payments To Acquire Restricted Investments at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's payments to acquire restricted investments?
- Alnylam Pharmaceuticals (ALNY) reported payments to acquire restricted investments of $4.10M in Q1 2026.
- How has Alnylam Pharmaceuticals's payments to acquire restricted investments changed year-over-year?
- Alnylam Pharmaceuticals's payments to acquire restricted investments decreased by 91.6% year-over-year, from $48.83M to $4.10M.
- What is the long-term trend for Alnylam Pharmaceuticals's payments to acquire restricted investments?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's payments to acquire restricted investments has grown at a 12.4% compound annual growth rate (CAGR), from $42.14M to $59.78M.
- What does payments to acquire restricted investments mean?
- Cash spent on investments that are restricted or earmarked for specific purposes.